Biologic and Biochemical Compound Evaluation Reagents

S5
Ligand Efficiency Calculations
S5
Protein Purification
S6
Isothermal Titration Calorimetry
S6
Crystallization and Diffraction Data Collection
S6
Structure Determination and Refinement
S7
Further General Experimental
S7
Synthesis and Characterization of Compounds
Protein Expression and Purification
The first bromodomain of Brd4 (Brd4-BD1, residues 42-168) was subcloned into a modified pET-15b(+) vector with an N-terminal His 6 tag followed by a Tobacco Etch Virus cleavage site. The encoded protein was expressed in the E. coli BL21(DE3) strain. E. coli cells transformed with the vector were grown 4 hours at 37 °C to an OD 600 of 1.0, in 1 liter LB media containing ampicillin (0.1 mg/ml). After 0.1 mM IPTG induction at 20 °C, cells were cultured overnight, and collected by centrifugation at 4,000 g. The pellet was suspended in 40 ml lysis buffer containing 50 mM HEPES, pH 7.4, 500 mM NaCl, 5 mM β-mercaptoethanol, and 1 mM PMSF. Cells were lysed on ice by sonication and cell debris was precipitated by centrifugation at 15,000 g for 30 minutes. Brd4-BD1 was purified by affinity chromatography on an Ni-NTA agarose column (Qiagen), using an elution buffer of 50 mM HEPES, pH 7.4, 500 mM NaCl, 5 mM bmercaptoethanol, and 50 mM of imidazole. After overnight TEV cleavage of the His 6 -tag, the cleaved tag was captured on affinity resin, and Brd4-BD1 was then purified to homogeneity by gel filtration before concentration to roughly 12 mg/ml in storage buffer (20mM HEPES, pH 7.4, and 150 mM NaCl). Samples for isothermal calorimetry were dialysed over night at 4 o C in a DTube™ Dialyser Midi, MWCO 3.5 kDa to a final buffer of 50 mM HEPES, pH 7.4 (at 25 o C), 150 mM NaCl. Protein handling was carried out on ice or in a cold room in all the above steps.
Isothermal Titration Calorimetry (ITC)
Experiments were carried out on a VP-ITC titration microcalorimeter from MicroCal™, LLC (Northampton, MA). All experiments were carried out at 15 o C while stirring at 295 rpm, in ITC buffer (50 mM HEPES pH 7.4 at 25 o C, 150 mM NaCl). The microsyringe (250 μL) was loaded with a solution of the protein sample (300 μM protein for the BETs, 950 μM protein for CREBBP and 600 μM for WDR9 (2) , in ITC buffer). All titrations were conducted using an initial control injection of 2 µl followed by 34 identical injections of 8 µl with a duration of 16 sec (per injection) and a spacing of 250 sec between injections. The heat of dilution was determined by independent titrations (protein into buffer) and was subtracted from the experimental data. The collected data were analyzed using MicroCal™ Origin software to yield enthalpies of binding (∆H) and binding constants (K B ) as previously described. 5 Thermodynamic parameters were calculated (∆G = ∆H -T∆S = -RTlnK B , where ∆G, ∆H and ∆S are the changes in free energy, enthalpy and entropy of binding respectively). In all cases a single binding site model was employed.
Crystallization and Diffraction Data Collection
Crystals of inhibitor-free BRD4-BD1 were first obtained in sitting drops of equal volumes of BD1 at 12 mg/ml and a precipitant solution containing 100mM sodium nitrate, 5% ethylene glycol, and 18% (w/v) PEG3350, as precipitant at 22 ºC. Rod-like crystals typically grew within 10 days to maximal size of 0.05x0.05x0.4 mm 3 . Native crystals were transferred and soaked in 1 mM compound 32 in the same crystallization buffer for 7 days. For data collection, a single crystal was flash frozen with a precipitant solution containing 20% (v/v) glycerol. Diffraction data for the BD1-compound 32 complex were collected from a flash-cooled crystal at 100°K using beam line 24ID-E at Argonne National Laboratory and were processed, integrated, and scaled together with HKL2000.
Structure Determination and Refinement
The structure of the BD1-compound 32 complex was solved by molecular replacement (MR) as implemented in Phenix 7 using the previous BD1-compound 1 structure (PDB 3MXF) as the search model. Structure refinement was carried out using conjugate-gradient energy minimization, torsion-constrained molecular dynamics simulated annealing, group B factor refinement, and individual B factor refinement protocols in Phenix 7 with 5% of the reflections omitted for free R factor calculation. Electron density peaks in difference Fourier maps at a height of above 3σ were assigned as water molecules in later refinement stages if they had reasonable geometry in relation to hydrogen bond donors or acceptors and their B-factors did not rise above 50 Å 2 during subsequent refinement. Model building was performed in Coot 8 guided by σ A -weighted 2Fo-Fc, Fo-Fc, and composite omit maps. The structure coordinates have been deposited in PDB under code 4WIV.
General Synthetic Information. All chemicals and solvents were purchased from commercial suppliers and used as received.
1 H NMR (300 MHz or 400 MHz) and 13 C NMR (75 MHz) spectra were recorded on a Varian NMR spectrometer. CDCl 3 was used as the solvent unless otherwise specified. LC-MS were performed on an Agilent 2100 system with a C 18 (5.0 m, 6.0 x 50 mm) LC column. The mobile phase is MeOH and water both containing 0.01% trifluoro acetic acid. A linear gradient was started from 75:25 MeOH/H 2 O to 100% MeOH in 5.0 min at a flow rate of 0.7 ml/min. The chromatograms were recorded at UV 210, 254, and 365 nm and subsequently used to determine compound purity. Low resolution mass spectra were recorded in APCI (atmospheric pressure chemical ionization). Flash chromatography separation was performed on YAMAZEN AI-580 system with Agela silica gel (12 or 20 g, 230-400 m mesh) cartridges. The microwave reactions were performed on a Biotage Initiator 8 system.
Procedures for the synthesis of compounds 5-9. These compounds were prepared by direct Suzuki coupling of fluorous arylsulfonates with the boronic ester. The Suzuki coupling reactions were carried out following the general procedure shown in Scheme 1. (10) . This compound was prepared following the reported procedure (Scheme 2). 9 Reductive amination of I afforded compound II, which was then N-acylated to give compound III. The Suzuki coupling of III afforded compound 10 as a brown solid (17% yield).
Synthesis of Ethyl-2-(N-(4-(3,5-dimethylisoxazol-4-yl)benzyl)-4-methoxybenzamido)-propanoate
1 H NMR (300 MHz, 
Scheme 3
Synthesis of 4-butyl-3-(4-(3,5-dimethylisoxazol-4-yl)-3-methoxyphenyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione (13).
This compound was prepared following the reported procedures (Scheme 5).
11 The Ugi 4-component reaction gave compound V which was cyclized to form VI. The Suzuki coupling of VI afforded 13 as a brown semisolid in 44% yield. 
Scheme 4
Synthesis of 10-(3-(3,5-dimethylisoxazol-4-yl)phenyl)-3,4,9,10-tetrahydro-1H-benzo[b]furo[3,4-e][1,4]diazepin-1-one (14)
. The synthesis of 14 was accomplished by a two-step synthesis shown in Scheme 6. A mixture of benzene-1,2-diamine (54 mg, 0.5 mmol), tetronic acid (53.5 mg, 0.5 mmol), and acetic acid (3 L) in 1 mL H 2 O was stirred at room temperature for 30 min. (15) . The synthesis of 15 was accomplished following the literature procedures (Scheme 6). The cycloaddition of -unsatuated ketone VIII with benzimidamide afforded pyrimidine IX. 12 This compound was subjected to the Suzuki coupling to give the final product. 
Scheme 5
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Synthesis of 4-(4-(6-(4-methoxyphenyl)-2-phenylpyrimidin-4-yl)phenyl)-3,5-dimethylisoxazole
4-(4-(6-(4-
1). N-Cyclohexyl-2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-]pyridin-3-amine
(20). 19% yield, 
6-Chloro-2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)-N-(4-methoxy-phenyl)imidazo-[1,2-
+ 1). N-(tert-butyl)-2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-c]pyrimidin-3-amine 2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)-N-isopropylimidazo[1,2-a]pyrazin
Synthesis of 2-((2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-a]pyrazin-3-yl)amino)acetic acid (26).
Compound 28 (0.284 g, 0.677 mmol, 1 eq) was dissolved in DCM (2.7 mL) and TFA General procedures for the synthesis of 40-44. The synthesis of these compounds was accomplished by a two-step synthesis shown in Scheme 9. The three-component reaction (Groebke-Blackburn-Bienayme reaction) was followed by the Suzuki coupling.
N-(tert-butyl)-2-(6-(3,5-dimethylisoxazol-4-yl)pyridin-3-yl)imidazo[1,2-a]pyrazin-3-amine (40). 25% yield, 
